Based on the PeptiDream Inc stock forecast from 0 analysts, the average analyst target price for PeptiDream Inc is not available over the next 12 months. PeptiDream Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of PeptiDream Inc is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, PeptiDream Inc’s stock price was JPY 2,570.00. PeptiDream Inc’s stock price has changed by -4.60% over the past week, +0.55% over the past month and +114.08% over the last year.
No recent analyst target price found for PeptiDream Inc
No recent average analyst rating found for PeptiDream Inc
Company Overview PeptiDream Inc
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. The company, through its subsidiary PDRadiopharma Inc., is involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. It has a collaboration with Novartis Pharma AG. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan. Read Less
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that...Read More
Frequently Asked Questions About PeptiDream Inc (4587:TSE) Stock
Stock Target Advisor's fundamental analysis for PeptiDream Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4587:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4587:TSE's stock to indicate what its average analyst target is.
4587:TSE stock's Price/Earning ratio is 21.32.
Our analysis grades 4587:TSE stock's Price / Earning ratio at B-. This means that 4587:TSE stock's Price/Earning ratio is above 18% of the stocks in the Biotechnology sector in the TSE exchange.
Based on this 4587:TSE may be undervalued for its sector.
The last closing price of 4587:TSE's stock was JPY 2,570.00.
The most recent market capitalization for 4587:TSE is JPY 364.21B.
Unfortunately we do not have enough analyst data on 4587:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PeptiDream Inc's stock.
As per our most recent records PeptiDream Inc has 745 Employees.
PeptiDream Inc's registered address is 3-25-23 Tonomachi, Kawasaki, Japan, 210-0821.
You can get more information about it from PeptiDream Inc's website at https://www.peptidream.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About PeptiDream Inc (4587:TSE) Stock
Stock Target Advisor's fundamental analysis for PeptiDream Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4587:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4587:TSE's stock to indicate what its average analyst target is.
4587:TSE stock's Price/Earning ratio is 21.32.
Our analysis grades 4587:TSE stock's Price / Earning ratio at B-. This means that 4587:TSE stock's Price/Earning ratio is above 18% of the stocks in the Biotechnology sector in the TSE exchange.
Based on this 4587:TSE may be undervalued for its sector.
The last closing price of 4587:TSE's stock was JPY 2,570.00.
The most recent market capitalization for 4587:TSE is JPY 364.21B.
Unfortunately we do not have enough analyst data on 4587:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PeptiDream Inc's stock.
As per our most recent records PeptiDream Inc has 745 Employees.
PeptiDream Inc's registered address is 3-25-23 Tonomachi, Kawasaki, Japan, 210-0821.
You can get more information about it from PeptiDream Inc's website at https://www.peptidream.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4587:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
